A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding

Carter, Ashley J. R.; Nguyen, Cecine N

doi:10.1186/1471-2458-12-526

Cited by 120 publications

(112 citation statements)

References 18 publications

(43 reference statements)

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…In general, our results for AYLL were high when compared to international reports, which inform of less than 7 years AYLL for colorectal and breast cancer (USA), 1.8 for prostate cancer, and 13.8 for lung cancer (6,7,16). In a Polish study, only male brain cancer and cervical cancer showed more than 10 years of life lost per death (AYLL 10.7 and 10.2, respectively) (16).…”

Section: Discussionmentioning

confidence: 65%

“…While YLL depend strongly on absolute frequency of deaths, AYLL are mostly determined by the age at which the deaths occur. Together, these measures provide meaningful indicators for decisions regarding resource allocations and design of prevention programs (7)(8)(9). They are also a useful base for comparison with other countries, and show the relative importance of different causes of death, taking into account the life expectancies of each population (10).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Years of life lost as a measure of cancer burden in Colombia, 1997-2012

2016

View full text Add to dashboard Cite

Introduction:There is hardly any information regarding years of life lost due to cancer in Colombia. Objective: To quantify total and average years of life lost due to cancer in Colombia, and to investigate changes in this burden between 1997 and 2012. Materials and methods: We obtained sex-specific data on age distribution, remaining life expectancy, deaths due to specific cancers and total number of deaths from the Colombian Departamento Administrativo Nacional de Estadísticas. We calculated years of life lost based on each individual´s age at death and the remaining life expectancy at that age; as for average years of life, we divided these by the number of deaths due to specific cancers. Results: The total number of cancer deaths increased by 33% between 1997 and 2012, comprising 15% of male and 20% of female deaths in the period 2010-2012. Total years of life lost due to cancer increased by 25.1% for males and 31.1% for females over the study period. The highest increases (>40%) were observed for colorectal, pancreas and kidney cancers in both sexes, for melanomas and bladder cancer in men, and for breast and ovarian cancer in women. Trends in average years of life lost were stable. Almost half (48-50%) of the years of life lost due to childhood cancers were due to leukemia. Conclusion: Cancer is an increasing health burden in Colombia. The high average years of life lost illustrate the poor prognosis of the disease compared to other countries. Primary prevention, early detection, and adequate and timely treatments are needed to change this situation.

show abstract

Section: Discussionmentioning

confidence: 65%

mentioning

confidence: 99%

Years of life lost as a measure of cancer burden in Colombia, 1997-2012

2016

View full text Add to dashboard Cite

show abstract

“…However, within oncology, the number of publications 4,6 , clinical trials 7 , and research funding [8][9][10][11] might not be distributed across cancer sites relative to the burden of disease. To our knowledge, no published study has described the interrelationships of disease burden, research output, and research funding within oncology.…”

Section: Introductionmentioning

confidence: 99%

Research Output and the Public Health Burden of Cancer: Is There Any Relationship?

et al. 2016

View full text Add to dashboard Cite

PurposeThe relative distribution of research output across cancer sites is not well described. Here, we evaluate whether the volume of published research is proportional to the public health burden of individual cancers. We also explore whether research output is proportional to research funding. MethodsStatistics from the Canadian and American cancer societies were used to identify the top ten causes of cancer death in 2013. All journal articles and clinical trials published in 2013 by Canadian or U.S. authors for those cancers were identified. Total research funding in Canada by cancer site was obtained from the Canadian Cancer Research Alliance. Descriptive statistics and Pearson correlation coefficients were used to describe the relationship between research output, cancer mortality, and research funding. ResultsWe identified 19,361 publications and 2661 clinical trials. The proportion of publications and clinical trials was substantially lower than the proportion of deaths for lung (41% deaths, 15% publications, 16% clinical trials), colorectal (14%, 7%, 6%), pancreatic (10%, 7%, 5%), and gastroesophageal (7%, 5%, 3%) cancers. Conversely, research output was substantially greater than the proportion of deaths for breast cancer (10% deaths, 29% publications, 30% clinical trials) and prostate cancer (8%, 15%, 17%). We observed a stronger correlation between research output and funding (publications r = 0.894, p < 0.001; clinical trials r = 0.923, p < 0.001) than between research output and cancer mortality (r = 0.363, p = 0.303; r = 0.340, p = 0.337). ConclusionsResearch output is not well correlated with the public health burden of individual cancers, but is correlated with the relative level of research funding.

show abstract

“…next-generation sequencing | tumor heterogeneity | GRIN2A | replication T ransitional cell carcinoma arising in the urinary bladder (TCC-UB) is a frequent cause of morbidity and mortality, and among patients in the United States, it is one of the most costly cancers to treat (1,2). The traditional somatic genetic basis of TCC-UB is a distinct division of low-grade papillary tumors from high-grade invasive tumors.…”

mentioning

confidence: 99%

Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer

Morrison

Liu

Woloszynska‐Read³

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Using complete genome analysis, we sequenced five bladder tumors accrued from patients with muscle-invasive transitional cell carcinoma of the urinary bladder (TCC-UB) and identified a spectrum of genomic aberrations. In three tumors, complex genotype changes were noted. All three had tumor protein p53 mutations and a relatively large number of single-nucleotide variants (SNVs; average of 11.2 per megabase), structural variants (SVs; average of 46), or both. This group was best characterized by chromothripsis and the presence of subclonal populations of neoplastic cells or intratumoral mutational heterogeneity. Here, we provide evidence that the process of chromothripsis in TCC-UB is mediated by nonhomologous end-joining using kilobase, rather than megabase, fragments of DNA, which we refer to as "stitchers," to repair this process. We postulate that a potential unifying theme among tumors with the more complex genotype group is a defective replication-licensing complex. A second group (two bladder tumors) had no chromothripsis, and a simpler genotype, WT tumor protein p53, had relatively few SNVs (average of 5.9 per megabase) and only a single SV. There was no evidence of a subclonal population of neoplastic cells. In this group, we used a preclinical model of bladder carcinoma cell lines to study a unique SV (translocation and amplification) of the gene glutamate receptor ionotropic N-methyl D-aspertate as a potential new therapeutic target in bladder cancer.next-generation sequencing | tumor heterogeneity | GRIN2A | replication

show abstract

A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding

Cited by 120 publications

References 18 publications

Years of life lost as a measure of cancer burden in Colombia, 1997-2012

Years of life lost as a measure of cancer burden in Colombia, 1997-2012

Research Output and the Public Health Burden of Cancer: Is There Any Relationship?

Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer

Contact Info

Product

Resources

About